Research and Markets has announced the addition of the "Lupus Nephritis - Epidemiology Forecast to 2023" report to their offering.
Lupus Nephritis - Epidemiology Forecast to 2023 report provides an overview of the disease and global historical and forecasted epidemiological data for the prevalent, diagnosed and treatable cases of Lupus Nephritis from 2013-2023 for the 7MM (United States, EU5 (France, Germany, Italy, Spain and UK) and Japan.
Lupus Nephritis is the most common kidney disorder caused by the life-threatening autoimmune disease such as Systemic Lupus Erythematosus (SLE). It is a leading cause of morbidity and mortality in patients with Systemic Lupus Erythematosus. It leads to inflammation of small blood vessels which play an important role in filtering waste materials in kidney. It also involves the inflammation of glomeruli. It is observed that approximately 50% to 60% of adults and 30% to 80% of children with lupus develop Lupus Nephritis. Frequency of developing Lupus Nephritis decreases after 5 years of Systemic Lupus Erythematosus.
Key Topics Covered:
Report Introduction
Lupus Nephritis: Overview
- Symptoms
- Pathophysiology
- Etiology
- Risk Factors
- Disease Burden
Unmet Needs
Epidemiology of Lupus Nephritis in 7MM
United States
Sex Specific Prevalence of Lupus Nephritis in United States
Age - Specific Prevalence of Lupus Nephritis in United States
EU5
United Kingdom
Sex Specific Prevalence of Lupus Nephritis in UK
Age - Specific Prevalence of Lupus Nephritis in UK
France
Sex Specific Prevalence of Lupus Nephritis in France
Age - Specific Prevalence of Lupus Nephritis in France
Italy
Sex Specific Prevalence of Lupus Nephritis in Italy
Age - Specific Prevalence of Lupus Nephritis in Italy
Spain
Sex Specific Prevalence of Lupus Nephritis in Spain
Age - Specific Prevalence of Lupus Nephritis in Spain
Germany
Sex Specific Prevalence of Lupus Nephritis in Germany
Age - Specific Prevalence of Lupus Nephritis in Germany
Japan
Sex Specific Prevalence of Lupus Nephritis in Japan
Age - Specific Prevalence of Lupus Nephritis in Japan
Appendix
For more information about this report visit http://www.researchandmarkets.com/research/sbhm4h/lupus_nephritis
View source version on businesswire.com: http://www.businesswire.com/news/home/20170324005206/en/
Contacts:
Laura Wood, Senior Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S.
Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related
Topics: Immune
Disorders Drugs